

LISTING OF CLAIMS

1-2. (canceled)

3. (original) A method of synthesis of an amonafide analog comprising combining a mitonafide analog comprising a 3-nitro group, ammonium formate, and a catalyst in an organic solvent to reduce said 3-nitro group.

4. (original) A method of synthesis of amonafide comprising combining mitonafide, ammonium formate, and a catalyst in an organic solvent.

5. (currently amended) A method of making synthesis of a naphthalimide diammonium salt comprising:
dissolving reacting a naphthalimide comprising at least two amine groups in an organic solvent;
and contacting said dissolved naphthalimide with an inorganic or organic acid to form a
naphthalimide diammonium salt, wherein at least 1.5 mole equivalents of said two amine groups
of said naphthalimide are protonated.

6. (original) The method of Claim 5 wherein said inorganic acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid.

7. (original) The method of Claim 5 wherein said organic acid is selected from the group consisting of acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malic acid, malonic acid, succinic acid, hydroxy succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid.

8-14. (canceled)

15. (currently amended) An aqueous solution consisting essentially of a dissolved naphthalimide amonafide-diammonium salt comprising at least two amine groups, wherein at least 1.5 mole equivalents of said two amine groups of said naphthalimide are protonated, said solution being suitable for administration by injection, said solution comprising a naphthalimide amonafide-at between 1 and 250 mg/mL, ~~said solution having a pH between 4.0 and 7.0.~~

16. (currently amended) An aqueous solution of naphthalimide amonafide-according to claim 15 suitable for parenteral, intramuscular, subcutaneous, intravenous, intraperitoneal or intratumoral administration.

17. (currently amended) An aqueous solution of a naphthalimide amonafide diammonium salt comprising at least two amine groups, wherein at least 1.5 mole equivalents of said two amine groups of said naphthalimide are protonated, said solution being suitable for administration by injection, said solution comprising naphthalimide amonafide-at between 10 and 100 mg/mL, ~~and said solution having a pH between 5.5 and 6.5.~~

18. (original) The solution according to claim 17, wherein said solution is substantially free of sugars.

19. (original) The solution according to claim 17, wherein said solution further comprises a pharmaceutically acceptable carrier.

20. (original) The solution according to claim 19, wherein said carrier is provided at a concentration between about 0.1 to 100 mg/mL.

21. (original) The solution according to claim 17, wherein said solution is provided in a unit dosage form.

22. (currently amended) A method for manufacturing a sterile pharmaceutical composition comprising a naphthalimide diammonium salt suitable for administration to a human, said method comprising:

(a) solubilizing a naphthalimide diammonium salt having at least two amine groups in an aqueous solution; and

(b) adding a base to said ~~neutralizing the~~ aqueous solution to form a naphthalimide salt, wherein 1.5 mole equivalents of said two amine groups are protonated; and ~~with a molar equivalent of base;~~

~~—(c)—~~ ~~adjusting the pH of the solution comprising said solubilized naphthalimide diammonium salt to about 6; and~~

~~(d)~~(c) sterilizing said aqueous solution.

23. (new) A method according to claim 3 or 4 further comprising forming an amonafide analog salt, solubilizing said amonafide analog salt in an aqueous solution and sterilizing said aqueous solution.

24. (new) A method of making a naphthalimide salt comprising dissolving a naphthalimide salt having two protonated amine groups in an aqueous solution and adding a base to form a solution of naphthalimide salt, wherein at least 1.5 mole equivalents of said two amine groups of said naphthalimide are protonated.

25. (new) A method according to claim 25 further comprising sterilizing said aqueous solution.

26. (new) A method according to claim 15 or 17 wherein said naphthalimide comprises amonafide.

27. (new) A method of making a naphthalimide salt comprising titrating an aqueous solution of a naphthalimide having at least two amine groups, with an acid or a base to produce a

naphthalimide solution where at least 1.5 mole equivalents of said two amine groups of said naphthalimide are protonated.

28. (new) A method according to claim 27 further comprising sterilizing said naphthalimide solution where at least 1.5 mole equivalents of said two amine groups of said naphthalimide are protonated.